Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026)
Codexis' (CDXS) quarterly Net Income towards Common Stockholders came in at -$8.7 million in Q1 2026, up 57.93% year-on-year from -$5.5 million in Q1 2025, and down 190.66% quarter-over-quarter from $9.6 million in Q4 2025.
Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Codexis' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.7 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 57.93% year-over-year to -$8.7 million in Q1 2026; TTM through Mar 2026 was -$32.0 million, a 57.04% increase from a year earlier, with the FY2025 full-year figure at -$44.0 million, up 32.63% from the prior year.
- Net Income towards Common Stockholders slipped to -$8.7 million in Q1 2026 per CDXS's latest filing, from $9.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.6 million in Q4 2025 and bottomed at -$34.9 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$11.5 million (2023), against an average of -$13.4 million.
- Across the five-year window, Net Income towards Common Stockholders slumped 545.28% in 2022 and surged 192.53% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$12.6 million in 2022, then soared by 42.94% to -$7.2 million in 2023, then tumbled by 44.27% to -$10.4 million in 2024, then jumped by 192.53% to $9.6 million in 2025, then slumped by 190.66% to -$8.7 million in 2026.
- Per Business Quant, the three latest CDXS Net Income towards Common Stockholders figures stand at -$8.7 million (Q1 2026), $9.6 million (Q4 2025), and -$19.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Codexis | 135.70 Mn | 70.56 Mn | 13.18 Mn | -8.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.70 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Mar 31, 2025 | -20.69 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -20.64 Mn |
| Jun 30, 2024 | -22.76 Mn |
| Mar 31, 2024 | -11.51 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -34.91 Mn |
| Jun 30, 2023 | -11.52 Mn |
| Mar 31, 2023 | -22.62 Mn |
| Dec 31, 2022 | -12.60 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -2.64 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | -4.27 Mn |